Super Exclusive: For the first time research analysis on Zydus's 'Gujarati vaccine', 300 scientists work day and night for a population of 130 crore.
- Zydus vaccine has undergone two phases of Zykov-D testing, producing 120 million doses a year
- Zydus began the complex vaccine development process last February after the covid epidemic was identified.
Since Prime Minister Narendra Modi visited Zydus Biotech in Ahmedabad on November 28, where the corona vaccine is being developed, the name Zycov-D has also been at the forefront of the corona vaccine being discussed in the country and the world.Divya Bhaskar got official details from Zydus about the formula and method of how the vaccine is being developed at the Zydus Vaccine Research Center at Changodar near Ahmedabad, the environment in which many scientists are working in this huge effort to make a vaccine. This is the first detailed report on the only corona vaccine being developed in Gujarat.
How did Zydus get started?
Zydus has vast experience as a leading pharma company in Gujarat in the field of vaccine manufacturing and has a global reputation. Zydus has previously successfully vaccinated against deadly diseases such as swine flu, tetanus, hepatitis B, and rubella, which is why the corona virus was identified in late December last year and shortly after the World Health Organization (WHO) declared the corona an epidemic. Began to think intensively about making.
Zydus chairman Pankaj Patel and M.D. Under the guidance of Sherville Patel, the company first focused on 3 issues.
1. The latest and global standards are adopted at every level, from formulas, technologies and devices to make vaccines.
2. The cost of the vaccine should be kept to a minimum so that it can be marketed at a very affordable rate and maximum people can get protection.
3. Care should be taken that the process of preservation and transportation of the vaccine is very conducive to the environment of India.
This was followed by the process of collaborating on various approvals, information, including research by various government bodies, including Zydase Drugs Controller General of India (DCGI), Department of Biotechnology (DBT) under the Ministry of Science, Indian Council of Medical Research (ICMR) and research. Coordinated with
The formula of the vaccine was decided after all the details, requirements were met. Earlier, the experience of vaccination process was also used for this. After all these preliminary preparations were completed, the Zydus vaccine was launched in February and was officially announced.
.jpg)
